Relmada Therapeutics Inc. (RLMD) 1.7000 $RLMD Enrollment

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Relmada Therapeutics Inc. (RLMD) 1.7000 $RLMD

Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark
PR Newswire - Mon Jun 29, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that patient enrollment in its proof-of-concept pharmacokinetic study with novel formulations of oral, enteric-coated buprenorphine (collectively BuTab, or REL-1028) being developed for both chronic pain and opioid dependence indications has reached the halfway point. Consistent with prior guidance, the company anticipates reporting top-line results in the second half of 2015.

Relmada Therapeutics to Present at 2015 BIO International Convention
PR Newswire - Mon Jun 15, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, chief executive officer, will present an overview of the Company at the BIO Business Forum, part of the 2015 BIO International Convention, on Wednesday, June 17, 2015, at 2:30 p.m. ET, at the Pennsylvania Convention Center, in presentation room Theater 2, Philadelphia, PA.

Postherpetic Neuralgia - Pipeline Review, H1 2015
M2 - Thu Jun 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hg24hw/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Aestus Therapeutics - Allergan - Arcion Therapeutics - Astellas Pharma - Daewoong Pharmaceutical - Daiichi Sankyo - Immune Pharmaceuticals - Intellipharmaceutics International - Merck & Co. - NeurAxon - Nuvo Research - Pfizer - Phosphagenics - Purdue Pharma - Relmada Therapeutics - Scilex Pharmaceuticals - Spinifex Pharmaceuticals - Teva Pharmaceutical Industries - Winston Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/hg...stherpetic
AGN: 312.13 (+8.03), IPCI: 3.48 (+0.03), MRK: 57.95 (+0.57), TEVA: 61.38 (-0.75), IMNP: 1.88 (+0.04)

Relmada Therapeutics Successfully Completes Phase 1 Single Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone
PR Newswire - Wed Jun 10, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has successfully completed a Phase 1 single ascending dose (SAD) clinical study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain.

Global Opium (Opioid) Addiction Pipeline Review, H1 2015 - 15 Companies & 20 Drug Profiles
M2 - Wed Jun 10, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhxtt9/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Camurus AB - Celtic Pharmaceutical Holdings L.P. - D&A Pharma SAS - Foresee Pharmaceuticals, LLC - Heron Therapeutics, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Omeros Corporation - Pfizer Inc. - Relmada Therapeutics, Inc. - Titan Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - (buprenorphine hydrochloride naloxone hydrochloride) - Buprenorphine Hemiadipate Hydrochloride - buprenorphine hydrochloride - buprenorphine hydrochloride depot - buprenorphine hydrochloride ER - buprenorphine hydrochloride long acting - buprenorphine hydrochloride SR - cannabidiol - FP-004 - MAL - methadone IR - naltrexone - naltrexone - OMS-405 - OMS-527 - PF-5006739 - samidorphan - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - TA-CD - Vaccine for Opium Addiction For more information visit http://www.researchandmarkets.com/research/hh...ium_opioid
BDSI: 8.64 (+0.15), INSY: 37.53 (+0.49), HRTX: 32.49 (+2.33), PFE: 34.36 (+0.50), ALKS: 64.22 (+1.88), ACUR: 0.92 (+0.03), OMER: 17.33 (+0.29)

Relmada Therapeutics, Inc. - Product Pipeline Review - 2014
M2 - Thu May 28, 6:31AM CDT
Product Pipeline Review - 2014

Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference
PR Newswire - Wed May 27, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 2015 LD Micro Invitational Conference on Monday, June 1, 2015 at the Luxe Sunset Hotel in Bel Air, California.

Relmada Therapeutics to Present at the 2015 Marcum MicroCap Conference
PR Newswire - Tue May 19, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 2015 Marcum MicroCap Conference on Thursday, May 28, 2015 in New York City at the Grand Hyatt Hotel.

Addiction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mhcllx/addiction) has announced the addition of the "Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acura Pharmaceuticals, Inc. - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - Beech Tree Labs, Inc. - BioDelivery Sciences International, Inc. - Bionex Pharmaceuticals LLC - Eli Lilly and Company - Embera NeuroTherapeutics, Inc. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Grunenthal GmbH - Heptares Therapeutics Ltd. - Immunovaccine, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Invion Limited - Johnson & Johnson - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Selecta Biosciences, Inc. - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Targacept, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mhcllx/addiction
BDSI: 8.64 (+0.15), PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), ACUR: 0.92 (+0.03), JNJ: 99.53 (+1.13), INSY: 37.53 (+0.49), TRGT: 2.68 (-0.06), GILD: 113.74 (+0.38), AZN: 66.45 (+1.90), ABBV: 69.23 (+1.26), ARNA: 4.29 (+0.04)

Relmada Therapeutics announces USPTO's patent allowance for proprietary SECUREL abuse deterrent technology platform
M2 - Wed May 13, 4:34AM CDT
Pharmaceutical company Relmada Therapeutics (OtherOTC:RLMD) disclosed on Tuesday that its new patent relating to its proprietary SECUREL abuse deterrent technology platform was allowed for issuance by the US Patent and Trademark Office (USPTO).

Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering SECUREL(TM), its Abuse-Deterrent, Extended-Release, Technology Platform for Opioids
PR Newswire - Tue May 12, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that Application No. 12/597,702 relating to its proprietary SECUREL abuse deterrent technology platform was allowed for issuance as a new patent by the U.S. Patent and Trademark Office (USPTO).

Global Insulin Patch Market Opportunity Analysis 2015
M2 - Wed May 06, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rkj3v9/global_insulin) has announced the addition of the "Global Insulin Patch Market Opportunity Analysis" report to their offering. Highly advanced technology like ultrasound and iontophoresis are being used for the development of modern insulin patches. Depending upon the type of technique, their prices may vary which may be out of reach of several patients. In long-term, it would be considered as inexpensive but high upfront cost may deter some diabetic patients. Benefits like greater control over blood glucose levels and ease of utilization are one of the most significant benefits of these technologies. It is expected that investigators would also explore the techniques like electroporation, thermal ablation and microdermabrasion for making insulin patches. These techniques are expected to increase the cost effectiveness due to which their market penetration would increase. In coming years, it is expected that investigators would be able to come forth with insulin patches having higher pharmacological benefits with lesser prices. Besides this, newer modalities are also expected to be developed due to which more sales are expected to be generated. Development of insulin patches are expected to pave the path for the development of large molecule based transdermal patches. This is going to be a major technological success due to which large number of patients would get more therapeutic benefits. Due to increased indications, more revenues are expected to generate from this field. Both molecules and formulations have to be revisited that will lead to new innovations. Moreover, pharmaceutical companies engaged in the production of insulin patches may venture in other diseases segment by using same technology. Insulin patches have yet not made place in global market but they will definitely encourage the other pharmaceutical companies to follow the lead. Pharmaceutical companies are expected to launch the first insulin patch in global market in next few years. "Global Insulin Patch Market Opportunity Analysis" Report Highlights: - Introduction to Insulin Patch - Mechanism Iontophoresis, Ultrasonic & Microneedle Insulin Patch - Global Insulin Patch Market Analysis - Global Insulin Patch Clinical Pipeline by Company, Indication & Phase - Global Insulin Patch Clinical Pipeline: 9 Patches - Highest Phase of Insulin Patch Development: Phase-II - Insulin Patch Patent Analysis Key Topics Covered: 1. Introduction to Insulin Patch 2. Comparison between Insulin Patches & Other Insulin Modalities 3. Mechanism of Insulin Patches 4. Emerging Trends in Insulin Delivery 5. Global Insulin Patch Market Analysis 6. Global Insulin Patch Market Dynamics 7. Future Prospects of Insulin Patch Market 8. Global Insulin Patch Clinical Pipeline by Company, Indication & Phase 9. Discontinued Insulin Patch in Clinical Pipeline 10. Competitive Landscape - Dermisonics - Encapsulation Systems - Encapsulife - Mesoblast - NeurogesX - NOLabs AB - Novo Nordisk - Phosphagenics - Relmada Therapeutics - Zosano Pharma For more information visit http://www.researchandmarkets.com/research/rk...al_insulin
NVO: 57.68 (+2.91), ZSAN: 8.26 (+0.49)

Relmada Therapeutics Commences Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine
PR Newswire - Tue Apr 21, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the commencement of a proof-of-concept pharmacokinetic study with its novel formulations of oral, enteric-coated buprenorphine (collectively BuTab, or REL-1028) being developed for both chronic pain and opioid dependence indications.

Relmada Therapeutics Receives Health Canada Clearance to Further Explore Promising NMDA Receptor Antagonist d-Methadone (REL-1017)
PR Newswire - Thu Apr 16, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has received clearance from Health Canada to continue dose escalation and explore higher doses of d-Methadone (REL-1017), the company's N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain. In the Phase 1 pharmacokinetic and pharmacodynamic study in healthy volunteers not previously exposed to opioid therapy, d-Methadone demonstrated a good safety profile with no dose-limiting side effects after the original four cohorts were exposed to increasingly higher doses. The trial will continue dose-escalation with the additional cohorts.

Relmada Therapeutics elects Dr Lisa Nolan as SVP of business development
M2 - Thu Apr 09, 5:43AM CDT
Pharmaceutical company
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 111

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 196

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 123

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 172

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 68

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 74

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading

Top 5 Most Recently Viewed Articles

Rocket Lab USA's Earnings Predictions and Market Insights

Updated Category News Views 157

Earned Expectations from Rocket Lab USA Rocket Lab USA (NASDAQ: RKLB) is gearing up for its quarterly earnings report, anticipated by investors with curiosity and optimism. The forthcoming announcement promises to deliver crucial insights into the company's financial health and growth trajectory. Expected Earnings Snapshot Analysts forecast that Rocket Lab will register...

Continue Reading
Upcoming Q2 Financial Results Announcement from Parkland

Updated Category News Views 108

Exciting News from Parkland Corporation Parkland Corporation, known for its dedication to providing quality fuel and convenience products, is gearing up for its next financial milestone. The company anticipates unveiling its second quarter results for 2025, a pivotal moment for investors and stakeholders alike. Key Announcement Details Scheduled to be disclosed after the...

Continue Reading
FLSmidth Secures Major Flotation Technology Contract for Iron Ore

Updated Category News Views 201

FLSmidth Secures Major Flotation Technology Contract for Iron Ore A leading Indian miner and steel producer has made a significant decision by selecting FLSmidth & Co. A/S to deliver a comprehensive flotation technology package for their state-of-the-art iron ore beneficiation plant. This facility is poised to be among the largest and most efficient of its kind globally,...

Continue Reading
Arthur J. Gallagher & Co. Plans Financial Results Conference

Updated Category News Views 118

Arthur J. Gallagher & Co. Announces Key Earnings Details Arthur J. Gallagher & Co. (NYSE: AJG) is gearing up to share its financial results for the fourth quarter of 2025. The announcement will be made after market closure on Thursday, January 29, 2026. Following this release, interested investors will find a printer-friendly version on the company’s official website,...

Continue Reading
Exelixis Faces Investor Scrutiny Amid Financial Reporting Concerns

Updated Category News Views 234

Exelixis under Investigation by Pomerantz Law Firm Pomerantz LLP, a renowned law firm, has initiated an investigation concerning investors of Exelixis, Inc. (NASDAQ: EXEL). This inquiry focuses on potential securities fraud or other unlawful practices involving the company and its leadership. Insights into Recent Financial Performance Recently, Exelixis reported its...

Continue Reading